Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep601 | Pituitary and Neuroendocrinology | ECE2020

A case of wolfram syndrome with primary hypogonadism

Calapkulu Murat , Erkam Sencar Muhammed , Ozturk Unsal İlknur , Duger Hakan , Kizilgul Muhammed , Bostan Hayri , Cakal Erman , Ozbek Mustafa

Introduction: Wolfram syndrome, is a rare autosomal recessive genetic disorder that is characterized by diabetes mellitus (DM), diabetes insipidus (DI), optic atrophy, and sensorineural deafness as well as various other possible disorders. DM is the first manifestation, and optic atrophy also onsets in the first decade of life. The onsets of DI and sensorineural deafness are in the second decade, urinary tract abnormalities are in the third decade, and neurologic abnormalities...

ea0022p583 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Plasma asymmetric dimethylarginine, symmetric dimethylarginine, homoarginine and arginine levels in patients with active acromegaly

Guldiken Sibel , Taskiran Bengur , Karadag C Hakan , Gunduz Ozgur , Bilir Betul Ekiz , Altun Betul Ugur , Tugrul Armagan

Aim: Acromegaly is associated with accelerated atherosclerosis and cardiovascular disease. Nitric oxide (NO) is enzimatically formed from L-arginine by endothelial nitric oxide synthase (eNOS). Several studies have shown that reduction in NO synthesis causes endothelial dysfunction and impaired endothelium-dependent vasodilation. Asymmetric dimethylarginine (ADMA), the endogenous inhibitor of NOS, accumulation plays a prominent role in the pathogenesis and in pr...

ea0073aep816 | Late Breaking | ECE2021

24-week impact of dapagliflozin treatment on body weight, body composition, and cardiac risk indicators of patients with type-2 diabetes mellitus

Akhanli Pinar , Hepsen Sema , Emre Arslan Ismail , Duger Hakan , Bostan Hayri , Kizilgul Muhammed , Ucan Bekir , Cakal Erman

AimsWe aimed to reveal the impacts of dapagliflozin, a sodium glucose transporter inhibitor (SGLT2i), on the body weight and body composition, cardiovascular risk indexes, and carotis intima-media thickness (CIMT).MethodsBody weights, body compositions measured by means of bioelectrical impedance, and CIMT in the baseline, the 12th, and the 24th week of 42 patients with type-2 diabetes mellitus receiving SGLT...

ea0073aep873 | Late Breaking | ECE2021

Changes in thyroid hormones and free triiodothyronine-to-free thyroxine ratio in euthyroid patients with obesity in terms of different glucose metabolism statuses

Hepsen Sema , Akhanli Pinar , Erkam Sencar Muhammed , Duger Hakan , Bostan Hayri , Kizilgul Muhammed , Emre Arslan Ismail , Cakal Erman

PurposeThyroid hormones are known to have an essential role in the regulation of energy homeostasis and glucose metabolism. Considering to literature data, variations of thyroid hormones within normal ranges change in obesity and type 2 diabetes mellitus (T2DM) in opposite ways. This study aims to evaluate thyroid hormone levels and fT3/fT4 ratio in different glucose metabolism statuses of euthyroid patients with obesity.Methods</p...

ea0079025 | Abstracts | BES2021

Hypoglycemia after initiation of CFTR modulator therapy in a cystic fibrosis patient without diabetes

Joke Vliebergh , Hakan Bor , Yskout Marie , Lieven Dupont , Natalie Lorent , Bleyenbergh Pascal Van , Pieter Gillard , der Schueren Bart Van , Ann Mertens , Chantal Mathieu , Roman Vangoitsenhoven

Background: Cystic fibrosis (CF) is a genetic disorder in which a dysfunctional cystic fibrosis transmembrane regulator (CFTR) chloride channel can result in multimorbidity, including severe respiratory disease and reduced pancreatic exocrine secretion and diabetes. Recently, CFTR modulator therapy, has emerged with the potential of improving respiratory function and remission of diabetes. The effect of CFTR modulator therapy on pancreatic function in patients without preexist...

ea0081p768 | Late-Breaking | ECE2022

Insulin-Like Growth Factor-I might be a predictor for severe nonalcoholic fatty liver disease in morbidly obese patients

Turgut Seda , Acarer Bugun Didem , Seyit Hakan , Pamuk Naim , Pişkinpaşa Hamide , Bozkur Evin , Karabulut Mehmet , Cakır İlkay

Aim: To compare the IGF-1, metabolic and clinical parameters among the ultrasonographically classified NAFLD groups, to examine the effect of weight loss on metabolic parameters and determine the factors that may predict the NAFLD severity in morbidly obese patients who underwent bariatric surgery.Method: This descriptive cross-sectional study was conducted in 316 morbidly obese patients (250 females, 66 males). The data of patients before and 1st year a...

ea0081ep1183 | Late Breaking | ECE2022

Weight loss induced by bariatric surgery may improve systemic inflammation: Preliminary results

Pamuk Naim , Turgut Seda , Seyit Hakan , Acarer Bugun Didem , Pişkinpaşa Hamide , Bozkur Evin , Karabulut Mehmet , Cakır İlkay

Background: Obesity is a widespread disease that causes chronic low-grade inflammation and related chronic diseases such as steatohepatitis, metabolic syndrome, diabetes mellitus (DM), and cancer. It is known that weight loss positively affects life expectancy by reducing obesity-related complications. Therefore, effective management of particularly morbidly obese patients is getting prominent in clinical practice. Bariatric surgery (BS) is the main effective treatment option ...

ea0090p441 | Pituitary and Neuroendocrinology | ECE2023

Prevalence and related risk factors of simple renal cysts and nephrolithiasis in acromegaly

Bostan Hayri , Kizilgul Muhammed , Calapkulu Murat , Kozan Kalkisim Hatice , Betul Gulden Topcu Fatma , Gul Umran , Duger Hakan , Hepsen Sema , Ucan Bekir , Cakal Erman

Background: The growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis has effects on renal growth and electrolyte regulation. However, data on adverse renal comorbidities such as renal cysts and stones in acromegaly is scarce. The current study aimed to investigate the prevalence of radiologically detectable renal comorbidities and possible related factors in the acromegaly population.Methods: A total of 125 patients with acromegaly (46.4&pm;11.6...

ea0049gp177 | Pituitary | ECE2017

Octreotide subcutaneous (s.c.) depot, a novel ready-to-use formulation, provides higher exposure and maintains response in patients with acromegaly and functioning neuroendocrine tumours (NETs) previously treated with long-acting octreotide: Results from a phase 2, open-label, multicentre, randomized study

Ferone Diego , Borson-Chazot Francoise , Cailleux Anne , Horsch Dieter , lahner Harald , Pivonello Rosario , Tauchmanova Libuse , Darstein Christelle , Olsson Hakan , Tiberg Fredrik , Pavel Marianne

Background: Octreotide s.c. depot is a novel, ready-to-use formulation administered via a thin needle, which may allow self-administration. In a phase 1 study in healthy volunteers, octreotide s.c. depot provided greater bioavailability with faster onset and greater IGF1 suppression than long-acting octreotide. Here, we present data from a phase 2 study evaluating pharmacokinetics (PK), efficacy, safety, and tolerability of octreotide s.c. depot in patients with acromegaly and...

ea0041gp72 | Diabetes | ECE2016

Olfactory and gustatory functions in patients with non-complicated type 1 diabetes mellitus

Baskoy Kamil , Ay Seyid Ahmet , Hira Serdar , Salihoglu Murat , Deniz Ferhat , Yıldırım Aynur , Altundag Aytug , Yonem Arif , Tekeli Hakan , Hummel Thomas

Introduction: Olfactory and gustatory dysfunction in patient with diabetes mellitus (DM) and its pathophysiology were studied in many previous studies. Some studies reported that there was a relationship between type 1 DM (T1DM) and olfactory and gustatory functions the presence of diabetic complications. However findings are limited and controversial. The aim of this study was to determine the relationship between olfactory and gustatory scores and patients with non-complicat...